SIGA Technologies - Q221 results
SIGA recently reported Q221 results, which featured $6.9m of revenue for the delivery of oral TPOXX to the Public Health Agency of Canada (PHAC). SIGA continues to work towards finalizing an order from an additional jurisdiction though timing is unknown due to the COVID-19 pandemic. The company has indicated that the size of this order would be similar to the initial orders received from Canada in 2020 and early 2021 (approximately $2.3m in 2020 and $3.4m in Q121).SIGA Technologies is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The company's primary product is an oral formulation of TPOXX?, an antiviral drug for the treatment of human smallpox disease caused by variola virus. The United States Food and Drug Administration has approved oral TPOXX? for the treatment of smallpox.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.